Bhupinder Sangha, MD
Critical Care Medicine · Seguin, TXNPI 1457594863
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 60.6% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $1,316, more than ten times the $69 reported in 2019.
Across 44 payments — averaging $48.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- GSK$129
- Actelion Pharmaceuticals US, Inc.$127
- Boston Scientific$118
- Tactile Systems Technology Inc$89
- Inari Medical, Inc.$85
- plus $291 from 12 others
What the payments were for
- Travel & lodging$1,06150%
- Food & beverage$97146%
- Education$995%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 12 | $1,291 |
| GSK | 7 | $129 |
| Actelion Pharmaceuticals US, Inc. | 2 | $127 |
| Boston Scientific | 2 | $118 |
| Tactile Systems Technology Inc | 3 | $89 |
| Inari Medical, Inc. | 2 | $85 |
| AbbVie | 3 | $52 |
| Grifols USA, LLC | 1 | $37 |
| Novartis | 2 | $32 |
| Sanofi | 2 | $31 |
| Johnson & Johnson | 1 | $27 |
| AstraZeneca | 1 | $20 |
| GE HealthCare | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $18 |
| Itamar Medical Inc | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $14 |
| Teleflex LLC | 1 | $14 |
| Masimo Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINQ II$861
How this compares
$2,130 in reported general payments places this provider in the 75th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 16 | $194,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $28,536 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 38 | $28,175 |
| FarxigaDapagliflozin Propanediol | 16 | $10,400 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 12 | $4,440 |
| Sevelamer Carbonate | 20 | $2,194 |
| Clonidine | 20 | $1,934 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 12 | $1,336 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 37 | $951 |
| Bumetanide | 21 | $841 |
| Losartan Potassium | 52 | $300 |
| Nifedipine ErNifedipine | 16 | $264 |
| Lisinopril | 12 | $262 |
| Carvedilol | 36 | $252 |
| Pravastatin Sodium | 16 | $168 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $127 | $194,95816 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Bevespi Aerosphere | $20 | $43,01566 claims |
| GSKTrelegy Ellipta | $129 | $28,53640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Seguin
- Steven DavidoffPlano$364K
- William BartekAustin$284K
- Edwin ParsleyHouston$283K
- Hector PayanEl Paso$245K
- Bindu AkkantiHouston$185K
- Faisal MasudHouston$155K
- Sergio Trevino CastilloHouston$133K
- Akinyinka AjelabiKingwood$109K
- Anthony OrtegonDallas$106K
- Gary WeinsteinDallas$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.